转移性乳腺癌患者中CA15.3和TPS与肿瘤病程的相关性。
The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer.
作者信息
Pronk L C, Stoter G, van Putten W L, de Wit R
机构信息
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
出版信息
J Cancer Res Clin Oncol. 1997;123(2):128-32. doi: 10.1007/BF01269892.
PURPOSE
This study was performed to determine the correlation of CA15.3 and TPS with disease course in patients with metastatic breast cancer.
METHODS
Levels of CA15.3 and tissue polypeptide antigen using the M3 monoclonal antibody (TPS) were determined in the serum of 60 patients with metastatic breast cancer. CA15.3 and TPS were measured at two assay times.
RESULTS
A change of more than 25% in the serum level of CA15.3 or TPS was highly correlated with tumor response. The association between response and change in marker levels was stronger for CA15.3 (P = 0.0001) than for TPS (P = 0.0005). Distinct mismatches between marker changes and the tumor response were observed for both CA15.3 and TPS.
CONCLUSION
CA15.3 and TPS are useful in the determination of response to treatment. Because of observed disagreement, marker changes can only be regarded as indicative of disease course.
目的
本研究旨在确定CA15.3和组织多肽特异性抗原（TPS）与转移性乳腺癌患者病程的相关性。
方法
测定60例转移性乳腺癌患者血清中CA15.3和使用M3单克隆抗体检测的组织多肽抗原（TPS）水平。在两个检测时间点测量CA15.3和TPS。
结果
CA15.3或TPS血清水平变化超过25%与肿瘤反应高度相关。CA15.3（P = 0.0001）的反应与标志物水平变化之间的关联比TPS（P = 0.0005）更强。CA15.3和TPS均观察到标志物变化与肿瘤反应之间存在明显不匹配。
结论
CA15.3和TPS有助于确定治疗反应。由于观察到的不一致性，标志物变化只能被视为疾病病程的指标。
Zotero 插件